De novo malignant disease after liver transplantation? Risk and surveillance strategies

Liver Transplantation

Volumn 19, Issue SUPPL. 2, 2013, Pages

  McCaughan, Geoffrey W ^a   Vajdic, Claire M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ALCOHOL LIVER DISEASE; ARTICLE; BASAL CELL CARCINOMA; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; COLORECTAL CANCER; GRAFT RECIPIENT; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; LIVER TRANSPLANTATION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

COMORBIDITY; FIBROSIS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES, ALCOHOLIC; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84892422343     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23738     Document Type: Article

References (42)

1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-1146.
2. Kinlen LJ, Webster AD, Bird AG, Haile R, Peto J, Soothill JF, Thompson RA. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet 1985;1:263-266.
3. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010;116:1228-1234.
4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.; for WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens - part B: biological agents. Lancet Oncol 2009;10:321-322.
5. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
6. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-2831.
7. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306:1891-1901.
8. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-815.
9. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10:1420-1427.
10. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. Am J Transplant 2013;13:1296-1304.
11. Sanchez W, Talwalkar JA, Gores GJ. "Will all liver transplantation patients eventually die from cancer?" J Hepatol 2006;44:13-18.
12. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl 2012;18:1277-1289.
13. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91.
14. Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005;80:759-764.
15. Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sørensen HT. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 2010;90:474-479.
16. Belloni-Fortina A, Piaserico S, Bordignon M, Gambato M, Senzolo M, Russo FP, et al. Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol 2012;92:411-415.
17. Herrero JI, España A, Quiroga J, Sangro B, Pardo F, Alvárez-Cienfuegos J, Prieto J. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl 2005;11:1100-1106.
18. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
19. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant 2013;13:174-183.
20. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR national registry data in the United States. Am J Transplant 2012;12:976-983.
21. Fernberg P, Edgren G, Adami J, Ingvar A, Bellocco R, Tufveson G, et al. Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients. Am J Transplant 2011;11:2472-2482.
22. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hézode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002;74:1103-1109.
23. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009;137:2010-2017.
24. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009;27:3354-3362.
25. Aberg F, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008;14:1428-1436.
26. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008;14:1588-1597.
27. Krynitz B, Edgren G, Lindelöf B, Baecklund E, Brattström C, Wilczek H, Smedby KE. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008 - a Swedish population-based study. Int J Cancer 2013;132:1429-1438.
28. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant 2010;10:1889-1896.
29. Baccarani U, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010;42:55-60.
30. Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012;18:269-274.
31. Benlloch S, Berenguer M, Prieto M, Moreno R, San Juan F, Rayón M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004;4:596-604.
32. Verran D, Mulhearn M, Dilworth P, Balderson G, Munn S, Chen J, et al. Nature and outcomes of the increased incidence of colorectal malignancy post liver transplantation in Australasia. Med J Aust. In press.
33. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-628.
34. Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009;15(suppl 2):S90-S94.
35. Herrero JI, Alegre F, Quiroga J, Pardo F, Iñarrairaegui M, Sangro B, et al. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant 2009;23:532-536.
36. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009;87:157-163.
37. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010;23:350-366.
38. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-2228.
39. Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009;9:2355-2361.
40. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005;11:89-97.
41. Herrero JI, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl 2011;17:402-408.
42. Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant; doi:10.1111/ajt.12384.